Clinical Trials Logo
  1. Home
  2. Seminoma
  3. NCT01887340

Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma — SEMITEP  

Seminoma Clinical Trial

Official title:
Therapeutic Strategy Guided by PET-TDM for Patients With Grade I or Metastatic Seminoma

Clinical Trial Summary

The purpose of the study is to evaluate the ration of patients getting an lighten therapeutic strategy after 18F-fluoro-désoxyglucose positron emission tomography (PET-TDM) in grade I (cohort 1) or metastatic (cohort 2) seminoma

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01887340
Study type Interventional
Source Gustave Roussy, Cancer Campus, Grand Paris
Contact Yohann LORIOT, MD
Phone 0142115276
Email yohann.loriot@gustaveroussy.fr
Status Recruiting
Phase Phase 2
Start date June 2013
Completion date June 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06133543 - Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer N/A
Recruiting NCT05529251 - De-escalation Study for Stage IIa/IIb < 3 cm Seminoma Phase 2
Completed NCT00705094 - Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients N/A
Active, not recruiting NCT03158064 - Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors Phase 2
Active, not recruiting NCT01593241 - Therapy De-escalation in Seminoma Stage IIA/B Phase 2
Recruiting NCT04876456 - A Phase II Trial of Cabozantinib With Patients With Refractory GCTs Phase 2
Active, not recruiting NCT03937843 - Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma Phase 2
Recruiting NCT04435756 - A Study of miRNA 371 in Patients With Germ Cell Tumors
Active, not recruiting NCT02834013 - Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Phase 2
Recruiting NCT06309745 - THERApy De-escalation for TESTicular Cancer
Recruiting NCT04914026 - MicroRNA as Markers in Testicular Cancer
Not yet recruiting NCT05142982 - Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced Seminoma N/A
Active, not recruiting NCT02375204 - Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors Phase 3
Recruiting NCT06144736 - PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND Phase 2
Recruiting NCT02341989 - Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer Phase 3